Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension

D'Alonzo, 1991, Survival in patients with primary pulmonary hypertension, Ann Intern Med, 115, 343, 10.7326/0003-4819-115-5-343 Simonneau, 2009, Updated clinical classification of pulmonary hypertension, J Am Coll Cardiol, 54, S43, 10.1016/j.jacc.2009.04.012 Galie, 2004, Guidelines on diagnosis and treatment of pulmonary arterial hypertension, Eur Heart J, 25, 2243, 10.1016/j.ehj.2004.09.014 Lang, 2004, Chronic thromboembolic pulmonary hypertension—not so rare after all, N Engl J Med, 350, 2236, 10.1056/NEJMp048088 Farber, 2004, Pulmonary arterial hypertension, N Engl J Med, 351, 1655, 10.1056/NEJMra035488 Ulrich, 2007, Bosentan therapy for chronic thromboembolic pulmonary hypertension, Swiss Med Wkly, 137, 573 Galie, 2009, A meta-analysis of randomized controlled trials in pulmonary arterial hypertension, Eur Heart J, 30, 394, 10.1093/eurheartj/ehp022 Humbert, 2010, Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension, Eur Respir J, 36, 549, 10.1183/09031936.00057010 Benza, 2010, Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL), Circulation, 122, 164, 10.1161/CIRCULATIONAHA.109.898122 Badesch, 2009, Diagnosis and assessment of pulmonary arterial hypertension, J Am Coll Cardiol, 54, S55, 10.1016/j.jacc.2009.04.011 Simonneau, 2002, Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial, Am J Respir Crit Care Med, 165, 800, 10.1164/ajrccm.165.6.2106079 Galie, 2009, Eur Heart J, 30, 2493, 10.1093/eurheartj/ehp297 Skoro-Sajer, 2008, A clinical comparison of slow- and rapid-escalation treprostinil dosing regimens in patients with pulmonary hypertension, Clin Pharmacokinet, 47, 611, 10.2165/00003088-200847090-00004 Schemper, 1996, A note on quantifying follow-up in studies of failure time, Control Clin Trials, 17, 343, 10.1016/0197-2456(96)00075-X Ederer, 1961, The relative survival rate: a statistical methodology, Natl Cancer Inst Monogr, 6, 101 Lang, 2006, Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension, Chest, 129, 1636, 10.1378/chest.129.6.1636 Barst, 2006, Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil, Eur Respir J, 28, 1195, 10.1183/09031936.06.00044406 Benza, 2011, Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials, J Heart Lung Transplant, 30, 982, 10.1016/j.healun.2011.03.011 Skoro-Sajer, 2007, Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension, J Thromb Haemost, 5, 483, 10.1111/j.1538-7836.2007.02394.x Humbert, 2010, Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era, Circulation, 122, 156, 10.1161/CIRCULATIONAHA.109.911818 Thenappan, 2009, Long-term outcomes in pulmonary arterial hypertension, Int J Clin Pract Suppl, 42, 10.1111/j.1742-1241.2009.02128.x Launay, 2009, Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil, Rheumatology (Oxford), 49, 490, 10.1093/rheumatology/kep398